All In Biotech

Drug Trial Radar · NCT05425446

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study)

Last checked: Nov 19, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Sep 19, 2022

Primary completion

Aug 9, 2024

Study completion Jan 17, 2025

Sponsor

Lead sponsor
Chugai PharmaceuticalIndustry
Sponsor type
Industry
First posted
Jun 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.

Conditions

  • Celiac Disease

Interventions

  • DONQ52Drug

    Subcutaneous (SC) injection

  • PlaceboDrug

    Subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higherTime frame: Up to 246 days
  2. Safety as assessed by Vital signs (blood pressure, body temperature, pulse rate, respiratory rate, percutaneous oxygen saturation)Time frame: Up to 246 days
  3. Safety as assessed by Electrocardiograms (ECGs; QT interval, heart rate)Time frame: Up to 246 days
  4. Safety as assessed by Laboratory tests (hematology, blood chemistry, coagulation and urinalysis)Time frame: Up to 246 days

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group

    Anniston, Alabama

  • Mountain View Clinical Research

    Denver, Colorado

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Clinical Site Partners

    Leesburg, Florida

  • Clinical Site Partners - Orlando

    Winter Park, Florida

  • Velocity Clinical Research - Boise

    Meridian, Idaho

  • Tandem Clinical Research

    Marrero, Louisiana

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Long Island Gastrointestinal Research Group

    Great Neck, New York

  • Columbia University Medical Center

    New York, New York

  • Lucas Research - Diabetes & Endocrinology Consultants, PC

    Morehead City, North Carolina

  • North Carolina Clinical Research

    Raleigh, North Carolina

  • Aventiv Research, Inc.

    Columbus, Ohio

  • Digestive Specialists Inc

    Dayton, Ohio

  • Velocity Clinical Research, Anderson

    Anderson, South Carolina

  • Alliance for Multispecialty Research

    Knoxville, Tennessee

  • Digestive Research of Central Texas

    Waco, Texas

  • Care Access Research

    Ogden, Utah

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • University of Sunshine Coast Clinical Trials Centre - Morayfield

    Morayfield, Queensland, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.